Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

STRATA-ALZ

Financiado

Optimizing stratification for trial design in Alzheimer’s disease

Alzheimer’s disease (AD) heterogeneity is associated with distinct risk factors, clinical manifestations, rates of cognitive decline, and comorbidities. However, this population variance is not properly incorporated in clinical tr... ver más

31/03/2025

LUNDS UNIVERSITET

207K€

Presupuesto del proyecto: 207K€

Líder del proyecto

LUNDS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-03-15

HORIZON-MSCA-2022-PF-01-01: MSCA Postdoctoral Fellowships 2022 ExpectedOutcome:

I+D

Cerrada hace 2 años

0% 100%

1 Participantes

LUNDS UNIVERSITET

206.89K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EPAD European Prevention of Alzheimer’s Dementia Consortium 60M€ Cerrado

ADDIT-CE Alzheimer's Disease Diagnostics Innovation and Translation t... 5M€ Cerrado

ADVANCE-AD Novel biomarkers for improving diagnostics, prognostics, and... 3M€ Cerrado

networkAD Network-based prediction of spreading of tau pathology in Al... 223K€ Cerrado

SAF2011-25463 CARACTERIZACION DEL DETERIORO COGNITIVO EN LAS FASES PRESINT... 182K€ Cerrado

ADEEPSLEEP Focusing on deep sleep-wake brain regions in the context of... 273K€ Cerrado

Duración del proyecto: 24 meses Fecha Inicio: 2023-03-15
Fecha Fin: 2025-03-31

Líder del proyecto

LUNDS UNIVERSITET No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 207K€

Descripción del proyecto Alzheimer’s disease (AD) heterogeneity is associated with distinct risk factors, clinical manifestations, rates of cognitive decline, and comorbidities. However, this population variance is not properly incorporated in clinical trial design, directly hampering successful development of treatments. As the field is shifting towards (early) secondary or event primary intervention, the overall objective of the current project is to optimize clinical trial design of an early AD population, by providing data-driven guidelines for sample stratification and outcome measures. To this end, I will assess neurobiological heterogeneity in ~2000 cognitively unimpaired (CU) and ~900 mildly impaired (MCI) subjects enrolled in the BioFINDER study from Lund University (host institution). Using their unique data-set, I aim to identify subtypes of amyloid-β (Aβ)-vascular interplay, the two most common co-occurring and interacting pathologies in the aging brain. Next, the role of neuronal function, microglial activation, and novel targets through proteomics analyses based on CSF/plasma biomarkers on disease progression within these subgroups will be determined. Finally, resulting tau-PET accumulation patterns and cognitive decline across domains across will be assessed. A main innovative aspect and strength of this project is the utilization of regional information available from the imaging modalities, an aspect of analyses which I have specialized in. In turn, the expertise of the host institution regarding fluid biomarkers and tau-PET imaging is paramount to support this multi-modal project. Finally, our respective experience with longitudinal study design will support a critical aspect of the project, which is lacking even in the most comprehensive studies to date. Unravelling heterogeneity in disease trajectories is paramount to optimize trial population selection and stratification, directly increasing the changes of positive trial outcomes.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores